---
title: "Galera Therapeutics 宣佈多倫多的 Biossil 公司以最高 1.05 億美元收購其超氧化物歧化酶模擬物組合"
description: "Galera Therapeutics 宣佈多倫多的 Biossil 以高達 1.05 億美元收購 Avasopasem 及其超氧化物歧化酶模擬物組合"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262237763.md"
published_at: "2025-10-22T12:04:00.000Z"
---

# Galera Therapeutics 宣佈多倫多的 Biossil 公司以最高 1.05 億美元收購其超氧化物歧化酶模擬物組合

> Galera Therapeutics 宣佈多倫多的 Biossil 以高達 1.05 億美元收購 Avasopasem 及其超氧化物歧化酶模擬物組合

Galera Therapeutics Announces Acquisition of Avasopasem and the Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million ...

### Related Stocks

- [GRTX.US - Galera Therapeutics](https://longbridge.com/zh-HK/quote/GRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Assessing Bio-Rad (BIO) Valuation After Recent Share Price Weakness And Longer-Term Return Pressures | Bio-Rad Laboratories (BIO) has experienced significant share price declines, prompting a reassessment of its valuation.  | [Link](https://longbridge.com/zh-HK/news/275997412.md) |
| ZAWYA-PRESSR: Mubadala Bio acquires full ownership of IDS and GMSC | Mubadala Bio has completed the full acquisition of Al Ittihad Drug Store (IDS) and Global Medical Supply Chain (GMSC) fr | [Link](https://longbridge.com/zh-HK/news/276104719.md) |
| Aqua Bio Technology Shareholders Back All Proposals at Extraordinary Meeting | Aqua Bio Technology ASA announced that shareholders approved all proposals at its extraordinary general meeting, indicat | [Link](https://longbridge.com/zh-HK/news/276072798.md) |
| Aqua Bio Technology adjusts ownership structure after NOK 10m private placement | Aqua Bio Technology ASA has completed a private placement of 2,000,000 new shares at NOK 5.00 each, coinciding with a pl | [Link](https://longbridge.com/zh-HK/news/276015231.md) |
| Aqua Bio Technology Sets Terms for Conditional Subsequent Share Offering | Aqua Bio Technology ASA has announced terms for a conditional subsequent share offering following a NOK 10 million priva | [Link](https://longbridge.com/zh-HK/news/275821047.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。